Discussion reveals concerns over cannabis rescheduling by HHS, highlighting DEA’s critical role in regulation.
Why shouldn't we reschedule cannabis? This is a question being bandied about from within the National Institute on Drug Abuse (NIDA), which wants to be able to study it, and in fact the entire Department of Health and Human Services (HHS), which in 2023 asked the Drug Enforcement Administration (DEA) to do just that.
No takes yet. Share an insight, caveat, or question.
Alison Knopf (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: